Skip to content
Catalyst

gabapentinWhat was measured

Measured, with no finding

68 endpoints

Show what was measuredHide what was measured
  • pruritus

    no effect, p = 0.6

    RR, 0.89; 95%CI 0.57–1.39, P = 0.600, Figs. 7 and)

    PMID 27577678 · one of two readings recorded this

  • publication bias for 24 h cumulative morphine consumption (Begg's test)

    no effect, p = 0.133

    there is no publication bias between the included studies for the cumulative morphine consumption by 24 h (P = 0.133, Fig. 4)

    PMID 27577678 · one of two readings recorded this

  • acute bipolar disorder symptom rating scales (MMPI-2, CGI-BP, YMRS, HAM-D)

    Each study assessed the efficacy of gabapentin using a different outcome measure. Quantitative analysis was not performed due to clinical and methodological heterogeneity.

    PMID 34819636 · one of two readings recorded this

  • all-cause drop-out, gabapentin in insomnia trials

    no effect, RR 0.96, 95% CI 0.59-1.57, n = 171

    The RR for all-cause drop-out was comparable for gabapentin and placebo (RR 0.96, 95% CI 0.59–1.57) (Supplementary Appendix, Fig. 25).

    PMID 34819636 · one of two readings recorded this

  • all-cause drop-out, insomnia trials

    no effect, (RR 0.96, 95% CI 0.59–1.57)

    The RR for all-cause drop-out was comparable for gabapentin and placebo (RR 0.96, 95% CI 0.59–1.57) (Supplementary Appendix, Fig. 25).

    PMID 34819636 · one of two readings recorded this

  • Clinical Global Impressions-Bipolar Version (CGI-BP) change score, 1-year long-term remitted bipolar disorder

    decreases, (gabapentin -2.1, placebo -0.6), n = 25

    There was a significant difference in favor of gabapentin in baseline-to-endpoint (1 year) change in CGI-BP score (gabapentin -2.1, placebo -0.6) and in use of sleeping medication (PSQI-item 6, gabapentin -1.1 vs. placebo -0.6).

    PMID 34819636 · one of two readings recorded this

  • Clinical Global Impressions-Bipolar Version (CGI-BP) change score at 1 year, gabapentin vs placebo, long-term remitted bipolar disorder

    decreases, (gabapentin -2.1, placebo -0.6), n = 25

    Not recorded as a finding: no CAT:outcome node exists for a bipolar-disorder global-impression severity score

    There was a significant difference in favor of gabapentin in baseline-to-endpoint (1 year) change in CGI-BP score (gabapentin -2.1, placebo -0.6) and in use of sleeping medication (PSQI-item 6, gabapentin -1.1 vs. placebo -0.6).

    PMID 34819636 · one of two readings recorded this

  • clinician-rated global bipolar disorder severity (CGI-BP), long-term maintenance treatment

    decreases, gabapentin -2.1 vs placebo -0.6 on CGI-BP change score at 1 year, n = 25

    Not recorded as a finding: no outcome node for CGI-BP exists in the vocabulary

    There was a significant difference in favor of gabapentin in baseline-to-endpoint (1 year) change in CGI-BP score (gabapentin -2.1, placebo -0.6) and in use of sleeping medication (PSQI-item 6, gabapentin -1.1 vs. placebo -0.6).

    PMID 34819636 · one of two readings recorded this

  • long-term bipolar disorder severity (CGI-BP)

    decreases, gabapentin -2.1 vs placebo -0.6 at 1 year, n = 25

    There was a significant difference in favor of gabapentin in baseline-to-endpoint (1 year) change in CGI-BP score (gabapentin -2.1, placebo -0.6) and in use of sleeping medication (PSQI-item 6, gabapentin -1.1 vs. placebo -0.6).

    PMID 34819636 · one of two readings recorded this

  • manic/depressive symptom rating scales (MMPI-2, YMRS, HAM-D, CGI-BP), acute bipolar disorder

    Quantitative analysis was not performed due to clinical and methodological heterogeneity.

    PMID 34819636 · one of two readings recorded this

  • manic symptom severity (YMRS), acute adjunctive treatment of bipolar disorder

    placebo group showed significantly greater YMRS improvement than gabapentin (adjunctive to valproate/lithium)

    Not recorded as a finding: no outcome node for YMRS exists in the vocabulary; not pooled due to heterogeneity

    The placebo group showed a significantly greater improvement in the total YMRS change score compared to gabapentin.

    PMID 34819636 · one of two readings recorded this

  • Panic and Agoraphobia Scale change score, gabapentin vs placebo, panic disorder, 8 weeks

    no effect

    Not recorded as a finding: no CAT:outcome node exists for the Panic and Agoraphobia Scale, and the finding is a single small trial with no pooled estimate

    However, eight weeks of flexibly dosed gabapentin was not more effective than placebo in patients with PD (comparable baseline-to-endpoint change on the Panic and Agoraphobia Scale).

    PMID 34819636 · one of two readings recorded this

  • Panic and Agoraphobia Scale change score, panic disorder, 8 weeks

    no effect

    However, eight weeks of flexibly dosed gabapentin was not more effective than placebo in patients with PD (comparable baseline-to-endpoint change on the Panic and Agoraphobia Scale).

    PMID 34819636 · one of two readings recorded this

  • panic disorder symptom severity (Panic and Agoraphobia Scale), gabapentin versus placebo

    no effect, comparable baseline-to-endpoint change between arms

    Not recorded as a finding: no outcome node for the Panic and Agoraphobia Scale exists in the vocabulary

    However, eight weeks of flexibly dosed gabapentin was not more effective than placebo in patients with PD (comparable baseline-to-endpoint change on the Panic and Agoraphobia Scale).

    PMID 34819636 · one of two readings recorded this

  • panic disorder symptoms (Panic and Agoraphobia Scale)

    no effect, comparable baseline-to-endpoint change

    However, eight weeks of flexibly dosed gabapentin was not more effective than placebo in patients with PD (comparable baseline-to-endpoint change on the Panic and Agoraphobia Scale).

    PMID 34819636 · one of two readings recorded this

  • preoperative anxiety, dose-stratified subgroup (gabapentin >600 mg versus placebo)

    decreases, high dose (>600 mg): SMD -1.30, 95% CI -1.72 to -0.87 (significant); low dose (≤600 mg): not significant

    Not recorded as a finding: subgroup of the overall preoperative-anxiety pooled estimate already claimed against CAT:outcome/anxiety-symptom-severity-pooled; recording the dose stratum separately would report a subgroup as the whole-population finding

    High doses (>600 mg) of gabapentin were found to be significantly effective in reducing preoperative anxiety (SMD -1.30, 95% CI -1.72 to -0.87), but low doses (600 mg) were not.

    PMID 34819636 · one of two readings recorded this

  • preoperative anxiety (pooled across scales)

    decreases, SMD -0.92, 95% CI -1.32 to -0.52

    Compared with placebo, both pregabalin (SMD -0.55, 95% CI -0.92 to -0.18) and gabapentin (SMD -0.92, 95% CI -1.32 to -0.52) were significantly more effective in reducing preoperative anxiety.

    PMID 34819636 · one of two readings recorded this

  • preoperative anxiety, pooled standardised mean difference across unnamed instruments

    decreases, (SMD -0.92, 95% CI -1.32 to -0.52)

    Compared with placebo, both pregabalin (SMD -0.55, 95% CI -0.92 to -0.18) and gabapentin (SMD -0.92, 95% CI -1.32 to -0.52) were significantly more effective in reducing preoperative anxiety.

    PMID 34819636 · one of two readings recorded this

  • sleep scale improvement in alcohol-dependence-related sleep disturbance, gabapentin versus placebo

    Not recorded as a finding: sentence names 'sleep scales' generically rather than the instrument (PSG/actigraphy/diary) required by the sleep-onset-latency/total-sleep-time nodes, and is a one-sided negation ('did not demonstrate improvement'), not a two-sided no_effect statement

    In participants with alcohol dependence and related sleep disturbance, gabapentin did not demonstrate improvement in sleep scales compared to placebo (Supplementary Appendix, Figs. 12 and 13).

    PMID 34819636 · one of two readings recorded this

  • sleep scale scores, alcohol dependence and related sleep disturbance

    In participants with alcohol dependence and related sleep disturbance, gabapentin did not demonstrate improvement in sleep scales compared to placebo (Supplementary Appendix, Figs. 12 and 13).

    PMID 34819636 · one of two readings recorded this

  • sleep scale scores in alcohol dependence and related sleep disturbance, gabapentin vs placebo, 2-trial random-effects meta-analysis

    Not recorded as a finding: one-sided negation ('did not demonstrate improvement') without a two-sided no_effect statement in the same sentence, and no specific sleep instrument is named

    In participants with alcohol dependence and related sleep disturbance, gabapentin did not demonstrate improvement in sleep scales compared to placebo (Supplementary Appendix, Figs. 12 and 13).

    PMID 34819636 · one of two readings recorded this

  • sleep scales in alcohol-dependence-related sleep disturbance

    n = 171

    In participants with alcohol dependence and related sleep disturbance, gabapentin did not demonstrate improvement in sleep scales compared to placebo (Supplementary Appendix, Figs. 12 and 13).

    PMID 34819636 · one of two readings recorded this

  • social anxiety disorder symptom scales, long-term gabapentin

    decreases

    A 14-week study of gabapentin in SAD showed significant improvement in symptoms compared to placebo across multiple clinician-evaluated and self-report rating scales.

    PMID 34819636 · one of two readings recorded this

  • social anxiety disorder symptom severity, long-term gabapentin treatment, multiple clinician-evaluated and self-report scales

    decreases

    Not recorded as a finding: no single named instrument; not pooled

    A 14-week study of gabapentin in SAD showed significant improvement in symptoms compared to placebo across multiple clinician-evaluated and self-report rating scales.

    PMID 34819636 · one of two readings recorded this

  • clinical global impression of change at 8 weeks, 2 studies

    no effect, (SMD = 0.07, 95% CI: −0.20–0.35), p = 0.6

    According to the result, the experimental group showed a slightly better clinical global impression of change compared with the control group (SMD = 0.07, 95% CI: −0.20–0.35, P = 0.6).

    PMID 35299589 · one of two readings recorded this

  • clinical global impression of change at 8 weeks

    no effect, SMD 0.07, 95% CI -0.20 to 0.35, P=0.6, p = 0.6

    According to the result, the experimental group showed a slightly better clinical global impression of change compared with the control group (SMD = 0.07, 95% CI: −0.20–0.35, P = 0.6).

    PMID 35299589 · one of two readings recorded this

  • incidence of adverse reactions, 6 studies

    decreases, (RR = 0.59, 95% CI: 0.45–0.79), p = 0.0003, n = 538

    The meta-analysis result of the six studies showed a lower incidence of adverse reactions in the experimental group compared with the control group (RR = 0.59, 95% CI: 0.45–0.79, P = 0.0003).

    PMID 35299589 · one of two readings recorded this

  • incidence of adverse reactions

    decreases, RR 0.59, 95% CI 0.45-0.79, P=0.0003 (favoring duloxetine, i.e. fewer adverse reactions than gabapentin), p = 0.0003, n = 538

    The meta-analysis result of the six studies showed a lower incidence of adverse reactions in the experimental group compared with the control group (RR = 0.59, 95% CI: 0.45–0.79, P = 0.0003).

    PMID 35299589 · one of two readings recorded this

  • response rate at week 2, 3 studies

    no effect, (RR = 1.05, 95% CI: 0.92–1.20), p = 0.47, n = 234

    The analysis results showed that the response rate in the control group was slightly higher than that in the control group (RR = 1.05, 95% CI: 0.92–1.20, P = 0.47).

    PMID 35299589 · one of two readings recorded this

  • sleep interference score at 8 weeks, 2 studies

    decreases, (SMD = -0.35, 95% CI: −0.63 to −0.08), p = 0.01

    The results showed that the sleep interference score at 8 weeks in the experimental group was lower than that of the control group (SMD = -0.35, 95% CI: −0.63 to −0.08, P = 0.01).

    PMID 35299589 · one of two readings recorded this

  • sleep interference score at 8 weeks

    decreases, SMD -0.35, 95% CI -0.63 to -0.08, P=0.01 (favoring duloxetine over gabapentin), p = 0.01

    The results showed that the sleep interference score at 8 weeks in the experimental group was lower than that of the control group (SMD = -0.35, 95% CI: −0.63 to −0.08, P = 0.01).

    PMID 35299589 · one of two readings recorded this

  • treatment response rate

    no effect, RR 1.05, 95% CI 0.92-1.20, P=0.47, p = 0.47, n = 234

    The analysis results showed that the response rate in the control group was slightly higher than that in the control group (RR = 1.05, 95% CI: 0.92–1.20, P = 0.47).

    PMID 35299589 · one of two readings recorded this

  • VAS pain score, all 7 studies

    no effect, (SMD = −0.26, 95% CI: −0.53–0.002), p = 0.07, n = 624

    The analysis results showed (SMD = −0.26, 95% CI: −0.53–0.002), P = 0.07) a slightly better outcome in the experimental group compared with the control group.

    PMID 35299589 · one of two readings recorded this

  • feeding tube (PEG) placement during chemoradiotherapy

    no effect, p = 0.962

    The pooled risk difference suggests there is no evidence for difference between the groups (RD = 0.64%, 95%CI: (− 25.8%, 27.1%), p = 0.962).

    PMID 36930339 · one of two readings recorded this

  • pain severity during chemoradiation, multiple unpooled patient-reported instruments (Likert, VAS, EORTC pain scale, Vanderbilt survey)

    Due to the variety of instruments selected by the investigators in these studies to quantify pain, it would be difficult to perform a meaningful meta-analysis of this data.

    PMID 36930339 · one of two readings recorded this

  • reactive feeding-tube (PEG) placement, pooled risk difference

    no effect, (RD = 0.64%, 95%CI: (− 25.8%, 27.1%), p = 0.962), p = 0.962

    The pooled risk difference suggests there is no evidence for difference between the groups (RD = 0.64%, 95%CI: (− 25.8%, 27.1%), p = 0.962).

    PMID 36930339 · one of two readings recorded this

  • reactive feeding tube placement rate during head and neck cancer chemoradiation, pooled risk difference between prophylactic gabapentin and control

    no effect, (RD = 0.64%, 95%CI: (− 25.8%, 27.1%), p = 0.962), p = 0.962

    Not recorded as a finding: this platform holds no node for the endpoint

    The pooled risk difference suggests there is no evidence for difference between the groups (RD = 0.64%, 95%CI: (− 25.8%, 27.1%), p = 0.962).

    PMID 36930339 · one of two readings recorded this

  • postoperative nausea after spine surgery

    no effect, n = 1388

    Not recorded as a finding: no outcome node for nausea exists in the vocabulary

    According to the head-to-head comparisons (eFigure 3C in Supplement 1), there is no significant difference between all different dosages of gabapentin and pregabalin.

    PMID 37556139 · one of two readings recorded this

  • postoperative nausea

    no effect, n = 1388

    According to the head-to-head comparisons (eFigure 3C in Supplement 1), there is no significant difference between all different dosages of gabapentin and pregabalin.

    PMID 37556139 · one of two readings recorded this

  • postoperative opioid consumption (morphine milligram equivalents) after spine surgery

    decreases, n = 1070

    Not recorded as a finding: no outcome node for opioid consumption exists in the vocabulary

    According to the head-to-head comparisons (eFigure 3B in Supplement 1), all different dosages of gabapentin and pregabalin have lower opioid consumption than placebo except for gabapentin 300 mg and 800 mg and pregabalin 75 mg.

    PMID 37556139 · one of two readings recorded this

  • postoperative opioid consumption

    decreases, n = 1070

    According to the head-to-head comparisons (eFigure 3B in Supplement 1), all different dosages of gabapentin and pregabalin have lower opioid consumption than placebo except for gabapentin 300 mg and 800 mg and pregabalin 75 mg.

    PMID 37556139 · one of two readings recorded this

  • postoperative parenteral opioid consumption, network SUCRA ranking

    decreases, (SUCRA, 91.0%; mean difference, −22.07%; 95% CI, −33.22% to −10.92%)

    According to SUCRA probability (Table 2), gabapentin 900 mg (SUCRA, 91.0%; mean difference, −22.07%; 95% CI, −33.22% to −10.92%) was most likely to be ranked the best.

    PMID 37556139 · one of two readings recorded this

  • postoperative VAS pain score

    decreases, n = 1427

    According to the head-to-head comparisons (eFigure 3A in Supplement 1), all different dosages of gabapentin and pregabalin have lower VAS scores than placebo except for gabapentin 400 mg, 800 mg, and pregabalin 75 mg.

    PMID 37556139 · one of two readings recorded this

  • postoperative Visual Analog Scale (VAS) pain score, network SUCRA ranking

    decreases, (SUCRA, 90.8%; mean difference, −2.67%; 95% CI, −3.80% to −1.54%)

    According to SUCRA probability (Table 2), gabapentin 900 mg (SUCRA, 90.8%; mean difference, −2.67%; 95% CI, −3.80% to −1.54%) was most likely to be ranked the best.

    PMID 37556139 · one of two readings recorded this

  • anxiety score compared to control intervention, instrument not named

    decreases, (MD = −1.32; 95% CI = −1.53 to −1.11)

    In addition, gabapentin supplementation could significantly decrease anxiety score compared to control intervention (moderate quality, MD = −1.32; 95% CI = −1.53 to −1.11; P <.00001; Fig. 7).

    PMID 38905436 · one of two readings recorded this

  • anxiety score

    decreases, MD -1.32, 95% CI -1.53 to -1.11, P<.00001

    gabapentin supplementation could significantly decrease anxiety score compared to control intervention (moderate quality, MD = −1.32; 95% CI = −1.53 to −1.11; P <.00001; Fig. 7).

    PMID 38905436 · one of two readings recorded this

  • incidence of postoperative nausea

    no effect, OR 0.51, 95% CI 0.15-1.73, P=.28, p = 0.28

    but showed no influence on nausea (very low quality, OR = 0.51; 95% CI = 0.15–1.73; P =.28; Fig. 9).

    PMID 38905436 · both readings recorded this

  • pain score at 24 hours postoperative

    decreases, MD -0.70, 95% CI -0.86 to -0.55, P<.00001

    resulted in substantially reduced pain scores at 24 hours (high quality, MD = −0.70; 95% CI = −0.86 to −0.55; P <.00001; Fig. 6).

    PMID 38905436 · one of two readings recorded this

  • postoperative bradycardia incidence

    no effect, (RR 1.00, 95% CI 0.21–4.81), n = 268

    Bradycardia: There were 2 studies including 268 patients reporting the prevention of postoperative bradycardia without statistically significant difference (RR 1.00, 95% CI 0.21–4.81) between patients using gabapentin and placebo (Table 2).

    PMID 40068032 · one of two readings recorded this

  • postoperative bradycardia

    no effect, RR 1.00, 95% CI 0.21-4.81, n = 268

    Bradycardia: There were 2 studies including 268 patients reporting the prevention of postoperative bradycardia without statistically significant difference (RR 1.00, 95% CI 0.21–4.81) between patients using gabapentin and placebo (Table 2).

    PMID 40068032 · one of two readings recorded this

  • postoperative dizziness incidence

    (RR 1.50, 95% CI 0.61–3.69), n = 146

    Dizziness: There were 2 studies including 146 patients reporting incidence of postoperative dizziness, compared with placebo, which was estimated without statistical reduction (RR 1.50, 95% CI 0.61–3.69; Table 2).

    PMID 40068032 · one of two readings recorded this

  • postoperative dizziness

    no effect, RR 1.50, 95% CI 0.61-3.69, n = 146

    There were 2 studies including 146 patients reporting incidence of postoperative dizziness, compared with placebo, which was estimated without statistical reduction (RR 1.50, 95% CI 0.61–3.69; Table 2).

    PMID 40068032 · one of two readings recorded this

  • postoperative headache incidence

    (RR 1.14, 95% CI 0.58–2.24), n = 236

    Headache: Headache was involved in 3 studies including 236 patients, there was no statistical significance of reduction in this side effect (RR 1.14, 95% CI 0.58–2.24) between patients taking gabapentin orally and who got placebo (Table 2).

    PMID 40068032 · one of two readings recorded this

  • postoperative headache

    no effect, RR 1.14, 95% CI 0.58-2.24, n = 236

    Headache was involved in 3 studies including 236 patients, there was no statistical significance of reduction in this side effect (RR 1.14, 95% CI 0.58–2.24) between patients taking gabapentin orally and who got placebo (Table 2).

    PMID 40068032 · one of two readings recorded this

  • postoperative hypotension incidence

    (RR 0.87, 95% CI 0.31–2.40), n = 268

    Hypotensive: Hypotensive was involved in 2 studies including 268 patients, compared with placebo, the pooled estimate did not exclude a statistical reduction in hypotensive (RR 0.87, 95% CI 0.31–2.40) in patients receiving gabapentin (Table 2).

    PMID 40068032 · one of two readings recorded this

  • postoperative hypotension

    RR 0.87, 95% CI 0.31-2.40, n = 268

    Hypotensive was involved in 2 studies including 268 patients, compared with placebo, the pooled estimate did not exclude a statistical reduction in hypotensive (RR 0.87, 95% CI 0.31–2.40) in patients receiving gabapentin (Table 2).

    PMID 40068032 · one of two readings recorded this

  • postoperative nausea (PON) incidence

    decreases, (RR 0.75, 95% CI 0.38–1.41)

    Compared with placebo, a probable reduction in PON without statistical significance (RR 0.75, 95% CI 0.38–1.41) was exposed in patients receiving gabapentin (Table 2).

    PMID 40068032 · one of two readings recorded this

  • postoperative nausea (PON)

    RR 0.75, 95% CI 0.38-1.41, n = 490

    Compared with placebo, a probable reduction in PON without statistical significance (RR 0.75, 95% CI 0.38–1.41) was exposed in patients receiving gabapentin (Table 2).

    PMID 40068032 · one of two readings recorded this

  • postoperative pruritus incidence

    (RR 0.76, 95% CI 0.40–1.46), n = 304

    Pruritus: 3 studies including 304 patients assessed postoperative pruritus. The pooled analysis did not show a statistically significant decrease, while with a reduced trend in this side effect (RR 0.76, 95% CI 0.40–1.46) in gabapentin group (Table 2).

    PMID 40068032 · one of two readings recorded this

  • postoperative pruritus

    n = 304

    Pruritus: 3 studies including 304 patients assessed postoperative pruritus.

    PMID 40068032 · one of two readings recorded this

  • postoperative shivering, 5-point shivering severity score (0 = none to 4 = shivering all over the body)

    decreases, (pooled RR 0.38, 95% CI 0.25–0.57)

    Not recorded as a finding: this platform holds no node for the endpoint

    Postoperative shivering (pooled RR 0.38, 95% CI 0.25–0.57) in the controlled group using placebo was more obvious than the study group adopting gabapentin.

    PMID 40068032 · one of two readings recorded this

  • postoperative shivering, graded on a 5-point shivering scale, pooled risk ratio across 6 RCTs

    decreases, pooled RR 0.38, 95% CI 0.25-0.57, n = 544

    Not recorded as a finding: this platform holds no node for the endpoint

    Postoperative shivering (pooled RR 0.38, 95% CI 0.25–0.57) in the controlled group using placebo was more obvious than the study group adopting gabapentin.

    PMID 40068032 · one of two readings recorded this

  • postoperative shivering incidence, 5-point shivering grade

    decreases, (pooled RR 0.38, 95% CI 0.25–0.57)

    Postoperative shivering (pooled RR 0.38, 95% CI 0.25–0.57) in the controlled group using placebo was more obvious than the study group adopting gabapentin.

    PMID 40068032 · one of two readings recorded this

  • postoperative shivering

    decreases, pooled RR 0.38, 95% CI 0.25-0.57, n = 544

    Postoperative shivering (pooled RR 0.38, 95% CI 0.25–0.57) in the controlled group using placebo was more obvious than the study group adopting gabapentin.

    PMID 40068032 · one of two readings recorded this

  • postoperative urine retention incidence

    decreases, (RR 0.50, 95% CI 0.24–1.03), n = 136

    Urine retention: 2 studies including 136 patients assessed urine retention after surgery, and the pooled estimate almost showed the significant reduction of postoperative urine retention (RR 0.50, 95% CI 0.24–1.03) in patients who took gabapentin orally (Table 2).

    PMID 40068032 · one of two readings recorded this

  • postoperative urine retention

    RR 0.50, 95% CI 0.24-1.03, n = 136

    2 studies including 136 patients assessed urine retention after surgery, and the pooled estimate almost showed the significant reduction of postoperative urine retention (RR 0.50, 95% CI 0.24–1.03) in patients who took gabapentin orally (Table 2).

    PMID 40068032 · one of two readings recorded this

  • postoperative vomiting (POV) incidence

    decreases, (RR 0.35, 95% CI 0.16–0.77), n = 136

    Postoperative vomiting (POV): POV was involved in 2 studies including 136 patients, the pooled estimate showed a statistical reduction in POV (RR 0.35, 95% CI 0.16–0.77) in patients who got gabapentin instead of placebo (Table 2).

    PMID 40068032 · one of two readings recorded this

  • postoperative vomiting (POV)

    decreases, RR 0.35, 95% CI 0.16-0.77, n = 136

    POV was involved in 2 studies including 136 patients, the pooled estimate showed a statistical reduction in POV (RR 0.35, 95% CI 0.16–0.77) in patients who got gabapentin instead of placebo (Table 2).

    PMID 40068032 · one of two readings recorded this